from Rs. 681 per kg. (fixed on 19-7-84) to Rs. 759/- per kg. (weighted average price) w.e.f. 17-8-88 based on the recommendation of BICP.

(e) and (f) if All bulk drug manufacturers have been directed to reduce the prices to the extent of duty reduce the prices to the extent of duty reduction as announced by the Government.

(g) No., Sir.

(h) Does not arise.

Statement

Among the drugs mentioned in part (a), this Ministry monitors the production of Dezamethasone, Betamethasone, Ethambutol, Glybenclamide and Fursemide only. details of stages of manufacture of these drugs to the extent available in respect of those companies who have reported production are given below:—

Name of drug/Name of Company	Stage of manufacture
I. *Dexamethasone*	
1. Merind	— Intermediate
2. Lupin Labs.	— —do—
3. Cadila Labs.	— —do—
II. *Betamethasone*	
1. Glindia	— Basic
2. Lupin Labs.	— Intermediate
3. Cadila Labs.	—do—
III. *Ethambutol*	
1. Themis Chemicals	— Intermediate
2. Cadila Labs.	
3. Lyka Labs.	
4. Lupin Lals.	
5. Taptakos & Brett.	
6. Ambalal Sarabhai Chemicals	
7. Jain Kaliawala	
IV. *Glybenclamide*	
Hoechst India Ltd.	— Basic
V. *Fursemide*	
1. Hoechst India Ltd.	— Basic
2. IDPL	— Basic.

Marketing of Products Manufactured by Small Scale Sector Units

4611. SHRI CHITTA BASU : Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1397 given in the Rajya Sabha on the 9th May, 1988 and state :

(a) What are the names of the products which M/s. Glindia and M/s. German Remedies are marke-

ting and which are manufactured by small sector units;

(b) What is the composition of each along with the strength and pack;

(c) Whether it is a fact that most of the price controlled products are being maketed by these companies without obtaining any price approval;

(d) If so, what is the approved price of each product under DPCO, 1979 and 1987 and what is the price at which each pack strength of each product is being sold;

(e) What are the names of the products where these companies are overcharging the consumers along with the extent of overcharging in each case ;

(f) Whether his Ministry has worked out the amount overcharged; and

(g) If so, what are the details thereof and by when it will be recovered from the companies?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) : (a) to (e)—A large number of scheduled as well as non-Scheduled formulations manufactured by some other companies including SSI units are being marketed by M/s. Glindia and M/s. German Remedies. The details required in the question are therefore, quite voluminous and not readily available. Times and efforts required for collection of these details will not be commensurate with the results likely to be achieved. Both the companies have been directed to advise the concerned manufacturer companies to seek necessary price approval under DPCO, 1987 for their products wherever necessary.

(f) to (g) Do not arise in view of reply to part (a) to (e) of the question above.

Price Control on Combinations of Drugs

4612. SHRI B. SATYANARAYAN REDDY.
DR. (SHRIMATI) SAROJINI MAHISHI:

Will the Minister of INDUSTRY be pleased to state :

(a) whether it is a fact that his Ministry has issued guidelines in respect of combinations of drugs for price control;

(b) whether it is a fact that according to the guidelines the combinnations of Category II drugs with decontrolled drugs will depend on major therapeutic ingredient and with vitamins it would be price controlled independent of major therepeutic, ingredient;

(c) whether it is a fact that the contents of guidelines are totally inconsistent with para 7 of DPCO, 1987;

(d) whether his Ministry got the guidelines cleared from the Department of Legal Affairs;

(e) if so, when and if not, what are the reasons therefor;

(f) what are the recommendations of the Expert Committee on the combinations of Category II drugs; and